3-Quinuclidinyl benzilate Stats & Data

- BZ is an extremely potent, long‑acting muscarinic acetylcholine receptor antagonist intended historically as a military incapacitating agent; “sub‑milligram” amounts can cause days‑long delirium, amnesia, ataxia, and severe disorientation. This is not a recreational drug and exposure should be considered a medical risk scenario.

- Onset is delayed (commonly 2–4 hours), which strongly increases the temptation to redose; redosing substantially raises the risk of prolonged incapacitation, heat injury, urinary retention, and hospitalization. Avoid any redosing.

- BZ markedly impairs sweating and heat dissipation (mydriasis, anhidrosis), creating a real risk of hyperthermia even at ambient temperatures; if exposure occurs, remain in a cool environment, remove excess clothing, use passive cooling, and seek medical evaluation for high temperature, agitation, or muscle rigidity.

- Vision is often severely affected (extreme mydriasis, blurred near focus) for 1–3 days or more—do not drive, cycle, swim, or engage in any hazardous activity until vision and cognition are clearly normal.

- Hydration is important but should be supervised; anticholinergics can cause both dry mouth and urinary retention. If unable to void for 6–8 hours with suprapubic discomfort, seek urgent care—catheterization may be required.

- In suspected anticholinergic toxicity, first‑line hospital care is supportive: cooling, IV fluids, electrolyte/CK monitoring, and cautious benzodiazepines for severe agitation. Physostigmine (a tertiary acetylcholinesterase inhibitor) can rapidly reverse delirium in pure anticholinergic toxidrome but must only be administered in a monitored medical setting due to seizure/bradyarrhythmia risk and is contraindicated in TCA co‑ingestion or QRS widening. Do not attempt any antidotes outside a hospital.

- Combining BZ with other anticholinergics (sedating antihistamines like diphenhydramine, TCAs, anticholinergic antipsychotics/antiemetics) markedly increases toxicity (confusion, hyperthermia, ileus, urinary retention). Alcohol, Z‑drugs, and opioids further impair judgement and breathing, compounding injury and aspiration risk. Stimulants may worsen agitation, hyperthermia, and rhabdomyolysis risk.

- Due to dose variability and idiosyncratic responses, “test dosing” is unsafe here: incapacitating IM doses are on the order of 6–8 µg/kg, and Erowid reports that <1 mg orally can cause profound effects for days.

- Tolerance data are limited. Military reports describe “second‑dose effects” 2–4 weeks after an initial exposure with faster onset and heightened peaks; repeated exposure increases unpredictability rather than safety. Cross‑tolerance with other antimuscarinics is plausible but unquantified.

- People with narrow‑angle glaucoma, prostatic hypertrophy/urinary obstruction, ileus, tachyarrhythmias, severe cardiovascular disease, or cognitive disorders, as well as children and older adults, are at elevated risk from anticholinergic toxicity; any suspected exposure warrants professional assessment.

- Mechanistically, BZ binds with very high affinity in the orthosteric pocket of muscarinic receptors; slow dissociation helps explain prolonged central effects even when plasma levels fall.

- Legal/forensic note: BZ is listed in the Chemical Weapons Convention (Schedule 2). Civilian availability is rare; unexpected “BZ” representations are often misidentifications of other anticholinergics.

- If someone seems intoxicated: do not leave them alone; prevent access to heat, water bodies, traffic, or weapons; avoid physical confrontation; call emergency services if there is fever, severe agitation, confusion, chest pain, seizure, inability to urinate, or loss of consciousness.